Tag

Pfizer

All articles tagged with #pfizer

business8 days ago•15 min saved

Next-gen obesity drug race tightens as pivotal readouts loom

Pharma is racing to commercialize next-generation obesity drugs as pivotal readouts approach from Lilly, Viking Therapeutics, and Pfizer; Lilly’s retatrutide shows potentially stronger weight loss and knee-pain relief in Triumph-4, Viking is testing maintenance dosing for VK2735, and Pfizer’s PF’3944 posted encouraging phase 2b results for monthly maintenance injections, signaling a crowded path to a multi-billion GLP-1 market by 2030.

via Pharma Voice|

#business #eli-lilly #glp-1

business22 days ago•2 min saved

Pfizer Beats Q1 Expectations, Bets on Pipeline to Sustain 2026 Outlook

Pfizer beat Q1 2026 estimates with adjusted EPS of 75 cents and revenue of $14.45 billion, reaffirming its 2026 guidance as growth from newly launched and acquired drugs offsets declines in Covid vaccine and Paxlovid sales; the company is pursuing long-term pipeline investments, notably a $10 billion Metsera acquisition, with 2026 targets of about $2.80–$3.00 in adjusted EPS and $59.5–$62.5 billion in revenue.

via CNBC|

#business #eliquis #metsera

health1 month ago•12 min saved

RFK Jr.'s Lyme pledge collides with vaccine history as Pfizer pushes a new jab

RFK Jr., as HHS secretary, pledges stronger action on Lyme disease with better diagnostics and treatment, but his anti-vaccine stance complicates Pfizer/Valneva’s plan to file a Lyme vaccine—the first in more than two decades. The prior Lyme vaccine Lymerix faced safety questions and weak uptake, illustrating the challenges Pfizer now faces, even as Lyme incidence rises with climate-driven tick expansion and researchers pursue vaccines and other preventive tools.

via CNN|

#health #lyme-disease #lymerix

health1 month ago•5 min saved

New Four-Dose Lyme Vaccine Shows About 70% Protection

Pfizer and Valneva announced phase 3 results for PF-0730740, a four-dose Lyme disease vaccine that achieved about 70% efficacy in preventing infection among people aged 5+ across the US, Canada, and Europe. The regimen requires four injections (two two months apart, then months five–nine, then one year later) and the vaccine is not yet approved; its impact on disease complications is unknown, but it could offer meaningful protection for those in endemic areas while continued tick-prevention steps remain important.

via Women's Health|

#health #lyme-disease #pfizer

health2 months ago•4 min saved

Lyme Vaccine Delivers Promising 70%+ Protection in Major Trial, Heads to FDA Review

Pfizer and Valneva’s VALOR Phase III trial for PF-07307405 shows about 73% efficacy at preventing confirmed Lyme disease, but the primary endpoint's 95% confidence interval is wide (15.8%–93.5%), likely due to milder Lyme activity during the study; a separate analysis confirms the lower bound above 20%, supporting FDA-approval steps. The vaccine targets the OspA protein to block Borrelia burgdorferi in ticks, and if approved could significantly boost Lyme prevention for high-risk groups.

via Gizmodo|

#clinical-trial #health #lyme-disease

health2 months ago•2 min saved

Pfizer-Valneva Lyme vaccine shows strong protection but misses statistical bar

An experimental Lyme vaccine from Pfizer and Valneva reduced the risk of Lyme disease by more than 70% in a trial, but it reportedly missed a key statistical endpoint, prompting regulators to scrutinize potential approval amid ongoing debates over trial methods and Lyme prevention.

via statnews.com|

#health #lyme-disease #pfizer

health2 months ago•2 min saved

Lyme vaccine shows strong efficacy in late-stage results but misses primary endpoint

Pfizer and Valneva's Lyme disease vaccine posted 73.2% efficacy starting 28 days after the fourth dose in a late-stage trial, but the study missed its primary endpoint under the worst-case scenario (15.8% efficacy in the initial analysis); a second analysis showed 74.8% efficacy, leading to plans for regulatory submissions, with no Lyme vaccine currently approved.

via NBC News|

#clinical-trial #health #lyme-disease

business2 months ago•2 min saved

Pfizer pushes ahead with Lyme vaccine despite late-stage trial miss

Pfizer intends to seek FDA approval for its Lyme disease vaccine candidate even after a late-stage trial failed to meet statistical goals due to too few Lyme cases; the company says efficacy exceeded 70% in vaccine recipients versus placebo, which they consider strong enough to move forward. Partner Valneva projects up to $1 billion in peak annual sales. The Phase 3 study started with about 18,000 participants but was reduced to roughly 9,400 due to site-quality issues, and Pfizer reports no safety concerns; the vaccine requires three initial doses followed by a booster and targets the outer surface protein A of the bacteria.

via CNBC|

#business #lyme-disease #pfizer

healthcare3 months ago•1 min saved

Most TrumpRx-listed drugs have cheaper generics, study finds

TrumpRx’s price list shows many branded meds have cheaper generic alternatives: for example, Pristiq can be found for about $200 for 30 days, while generics cost under $30 and even as low as $16.65 on CostPlusDrugs. Experts warn the site may not benefit cash buyers and could steer patients toward pricier branded options, though the White House says it aims to offer the lowest-cost branded choices. Regulators note generics are generally safe and equivalent, though some critics point to FDA testing gaps highlighted by investigations.

via Axios|

#costplusdrugs #drug-pricing #generics

markets3 months ago•3 min saved

Pfizer slides as 2026 revenue is seen pressured by patent cliffs

Pfizer shares fell in premarket trading after reaffirming its 2026 outlook, projecting roughly a $1.5 billion revenue decline as products lose market exclusivity. The headwind is driven by patent cliffs, tariffs, and about $5 billion in COVID-19 product revenue, even as vaccines and drugs such as Abrysvo, Eliquis, Padcev, and Prevnar show growth.

via Seeking Alpha|

#markets #patent-cliffs #pfe

markets3 months ago

Premarket Movers Spotlight: Palantir, Merck, Pfizer Lead Early Trading

Palantir (PLTR), Merck (MRK), and Pfizer (PFE) were among the biggest movers in premarket trading, with Market Insider noting several other names as the session began.

via CNBC|

#markets #merck #palantir

business3 months ago•2 min saved

Pfizer's long-acting obesity shot shows promise with monthly dosing in mid-stage trial

Pfizer reported mid-stage results for PF′3944, an ultra-long-acting GLP-1 obesity drug, showing up to 12.3% weight loss vs placebo at week 28 and about 10.5% when including discontinuations, with no plateau after switching to monthly dosing—suggesting continued weight loss through week 64. The data imply monthly dosing could match weekly regimens, offering convenience in a market led by Eli Lilly and Novo Nordisk. Pfizer plans 10 phase 3 trials this year; modeling suggests a higher monthly dose could achieve roughly 16% weight loss at week 28. The drug was generally well tolerated with mostly mild to moderate GI side effects and some discontinuations due to side effects in both weekly and monthly phases.

via CNBC|

#business #glp-1 #monthly-dosing

business3 months ago•3 min saved

Pfizer bets on Metsera and cost cuts as Q4 beats amid waning Covid sales

Pfizer beat Q4 estimates with adjusted EPS of 66 cents on $17.56 billion in revenue, despite weaker demand for its Covid vaccine and Paxlovid; it reaffirmed a modest 2026 outlook, plans about $7.7 billion in cost cuts by 2027, and is betting on long-term growth from the Metsera acquisition, including obesity therapy data, while facing ongoing price pressure in Medicaid and competitive pressures on older drugs.

via CNBC|

#business #covid-19 #earnings

business3 months ago•15 min saved

Pfizer's Q4 Preview: Beat Likely, but Upside Hinges on Drug Updates and US Pricing Policy

Pfizer is set to report Q4 earnings before the open, with expectations for EPS of $0.57 on about $16.85 billion in revenue, continuing its streak of beating earnings in 15 of the last 16 quarters. Yet upside looks limited given 2026 guidance, so focus may shift to new drug data (VESPER-3 obesity study, Lyme vaccine, prostate cancer treatment, NSCLC therapy) and potential US pricing pressure from Medicare negotiations starting in 2028. Options imply roughly a 3.6% move post-earnings, and Wall Street holds a Moderate Buy with a around $28.5 average target (AI target about $29).

via TipRanks|

#business #earnings #medicare-price-negotiations

business3 months ago•2 min saved

Dividend Stocks Set for a 2026 Comeback as Rates Stay Low

High-quality dividend stocks are expected to rally as government actions likely keep long-term rates suppressed, making cash less attractive. The piece highlights sustainable payers like SCHD, mispriced midstream names such as ONEOK, and value plays like Pfizer and Conagra Brands, noting OKE's 5.6% yield and potential upside if multiples normalize, while warning inflation and sector headwinds require selective stock picking.

via Seeking Alpha|

#business #conagra-brands #dividend-stocks